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A homeopathic remedy for early COPD“Let’s Diagnose COPD Early!” was the title of an editorial
written by the late great Doctor Tom Petty over 35 years
ago.1 Towards the end of his editorial, promoting the
widespread use of office spirometry to detect COPD, he
stated, “It must be honestly admitted that studies to
establish the value of early or so-called preventive therapy
are yet to be established.” The U.S. National Heart Lung
and Blood Institute and the American Thoracic Society then
held a workshop on screening programs for early diagnosis
of airway obstruction to discuss the “rapidly developing
confusion about pathophysiologic abnormalities associated
with early airway obstruction.” The eminent group of
respiratory scientists at the 1973 workshop included
Doctors Nicholas Anthonisen, Margaret Becklake, Sonia
Buist, Reuben Cherniack, Charles Fletcher, Claude Lenfant,
Peter Macklem, Solbert Permutt, and others.2 They
concluded that “a mass screening program for early
detection of chronic bronchitis and emphysema should not
be undertaken at this time” . because “these diseases
have a long course and currently available treatment is at
best no more than palliative.” Very little has changed since
then, except that many large studies have proven conclu-
sively that COPD inhalers do not improve the course of the
disease in smokers. However, because of financial impera-
tives, during the past decade, much more has been written
about this topic than is known. The editorial review “New
horizons in early stage COPD” in this issue by Marc
Decramer and colleagues,3 resulting from a meeting spon-
sored by Boehringer and Pfizer, is no exception.
The manufacturers and distributors of COPD inhalers are
diligently working to expand their 5 billion Euro per year
worldwide market. They are generously funding medical
education companies (MECs) to hold meetings at luxurious
resorts for key opinion leaders to discuss the value of early
detection and treatment of mild COPD. The MECs then pay
skilled medical writers to produce reviews and editorials
which promote this concept as “Early detection and
management of COPD guidelines from the National COPD
Awareness Panel”.4 Some experts worry about the ethics of
these marketing methods, even when professional medical
societies are involved.5,6
Even after 35 years, there is no consensus definition of
“early” COPD. Decramer and colleagues suggest that mild0954-6111/$ - see front matter ª 2011 Elsevier Ltd. All rights reserved
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FEV1 above 50% predicted is early COPD. However, this
arbitrary range is exceedingly broad: from older adults
with entirely normal lung function7,8 and only a 10% like-
lihood that even if they continue smoking they will expe-
rience rapid loss of lung function and develop clinically-
important COPD during the subsequent 20 years (even if
they continue smoking) e to smokers who have irrevocably
lost half of their lung function causing dyspnea on exertion
and over a 90% likelihood that they have clinically-
important COPD which will continue to progress unless
they stop smoking.
Neither smokers nor never-smokers who fall into GOLD
stage I should labeled as having COPD. Their FEV1 is normal.
Giving them a diagnosis of COPD often harms the patient
since it stops the search for the real cause of their symptoms:
a diseasewhichmay be successfully treated. A chronic cough
in an adult smoker is as likely to be due to asthma, post-nasal
drainage due to rhino-sinusitis, or gastro-esophageal reflux,
as chronic bronchitis.9 If they report dyspnea on exertion it is
more likely be due to obesity, cardiovascular decondition-
ing, anemia, chronic heart failure, asthma, emphysema
without airway disease, or other lung diseases.
The higher mortality rates for older adults in GOLD stage
I reported by Mannino and colleagues10 were due to
cardiovascular diseases, not COPD. The higher rates of
“COPD-related” hospitalizations during the 11 years of
follow-up were due to other smoking-related diseases or
asthma, not severe COPD exacerbations. Any mention of
COPD in the medical record (not a discharge diagnosis) was
used to define a COPD-related hospitalization. A much
larger study in Sweden showed no difference in hospital
admissions (all cause, cardiovascular, asthma, or COPD)
with GOLD stage I after 20 years of follow-up.11
GOLD stage I is not associated with dyspnea.12 Samples
of adults with GOLD stage I do not have limitation of peak
oxygen consumption during exercise.13 Twelve older
patients who were referred to a pulmonary specialist for
chronic dyspnea, and then categorized as GOLD stage I,
were shown to have dyspnea-limited exercise.14 However,
tests such as BNP and echocardiography were not done to
detect heart failure and their mean DLCO was lower and
mean residual volumes higher than the control group,.
1574 Editorialsuggesting that some of them had upper lobe emphysema
as a cause of their dyspnea (not airway disease).
Somewhere below the middle of the GOLD stage II
category (FEV1 below 65% predicted), the likelihood
that smokers have clinically-important COPD increases
substantially, with dyspnea on exertion due to airflow
limitation (which might respond to bronchodilator ther-
apy), and a significantly increased risk of subsequent
rapid loss of lung function (disease progression).
Spirometry and bronchodilator responsiveness only
predict 10% of the variability in the subsequent loss of
lung function in continuing smokers in GOLD stages I and
II15 and there are currently no good biochemical markers
(from blood, exhaled breath, or induced sputum) of COPD
disease activity.16
The only effective intervention in early COPD is smoking
cessation.17 However, confronting smokers with spirometry
results does not improve smoking cessation rates.18 All
smokers (regardless of spirometry testing) should be helped
to quit, using pharmacotherapy proven to help those who
are unable to quit without it.
Decramer and colleagues listed recent studies designed
to measure the efficacy of various types of COPD inhalers.3
None significantly affected the rate of decline. From the
patients’ standpoint there was also little to offer in these
studies in terms of dyspnea, the major symptom in COPD.
GOLD stage II participants in the active treatment arms of
the TORCH and UPLIFT studies19,20 reported statistically
significant better quality of life (St George’s Respiratory
Questionnaire e SGRQ) than those using placebo inhalers,
but the improvement was well below the minimum clini-
cally-important difference for the SGRQ (-4.0 units).21 If
their dyspnea is not relieved soon after taking a broncho-
dilator, the patient with early COPD should not be given
a long-acting bronchodilator to take every day.
The rate of decline in post-bronchodilator FEV1 in the
TORCH study was 16 ml per year better in the combination
inhaled long-acting beta-agonist and corticosteroid inter-
vention group.19 In UPLIFT, the rate of decline in post-
bronchodilator FEV1 was 6 ml per year better in the tio-
tropium group compared to the placebo group, an annual
advantage of 0.3% in the rate of decline in lung function.20
After ten years of faithfully taking an inhaler every day,
these patients would only have 3e4% better lung function
(on average).
Thirty-five years later, a new, widely endorsed COPD
guideline concludes: “There is limited and conflicting
evidence of health benefits resulting from initiation of
inhaled bronchodilators (anticholinergics or long-acting
beta-agonists) in symptomatic patients with FEV1 between
60% and 80% predicted as documented by spirometry”.22
Many patients with a diagnosis of COPD do not have
airway obstruction and it is a waste of money and risks
serious side effects if they are prescribed a daily COPD
inhaler.23 A placebo inhaler, taken regularly by patients
with COPD who believed in the remedy, was associated with
much lower exacerbation and mortality rates in the TORCH
study (when compared to those with poor adherence).23,24
After smoking cessation, perhaps a homeopathic inhaler is
the best remedy for early COPD.
This editorial is dedicated to the memory of Peter
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